A woman who developed breast cancer after taking combination hormone therapy drugs including Premarin, Provera and Prempro for 15 years won a $5 million award against drug companies Wyeth and Upjohn this month.
Product liability plaintiffs should have been permitted to introduce expert testimony linking the short-term use of Prempro to a risk of breast cancer, the 8th Circuit has ruled in reversing a summary judgment.
Drug maker Pfizer has set aside an additional $330 million to cover its liability for hormone-replacement therapy drugs like Prempro, Premarin and Provera, indicating in a regulatory filing that total payouts for those claims will probably approach $1.2 billion.
A 65-year-old elementary school principal has won a $4 million verdict in Connecticut federal court against the maker of the menopause drug Prempro for causing her breast cancer.
A product liability plaintiff could not show that the alleged failure of pharmaceutical companies to warn about the dangers of their hormone therapy drugs was the proximate cause of her breast cancer, a U.S. District Court in South Carolina has ruled in granting summary judgment.
A product liability lawsuit against drug maker Wyeth was not barred by the plaintiff’s failure to declare her claim as an asset in her bankruptcy case prior to obtaining a discharge of debts, a U.S. District Court in Mississippi has ruled in denying summary judgment.
A $28 million award of punitive damages was not unconstitutionally excessive in a product liability case brought by a woman who contracted breast cancer after taking hormone replacement therapy drugs, a Pennsylvania appellate court has ruled in reversing judgment.
Evidence of Wyeth’s marketing campaign for “off-label” Prempro uses was admissible in a product liability case brought by a woman who contracted breast cancer after taking the drug, a Pennsylvania appellate court has ruled.
Drug maker Pfizer and its affiliates have settled nearly half of the product liability claims involving the hormone-replacement therapy drugs Prempro, Premarin and Provera, according to a regulatory filing.
After a jury in Philadelphia awarded $76 million in compensatory damages to three women who claimed that the hormone therapy drugs Prempro, Premarin and Provera caused their breast cancer, drug maker Wyeth Pharmaceuticals settled the cases for a confidential amount.